These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical efficacy of ceftazidime in inflammatory diseases in the field of gynecology].
    Author: Okamura K, Nakakuki M, Yamada K, Furukawa K, Sato A, Nagai H, Koga S, Igarashi A, Nakagawa K.
    Journal: Jpn J Antibiot; 1984 Jan; 37(1):1-5. PubMed ID: 6374190.
    Abstract:
    Ceftazidime ( CAZ ) was evaluated for its clinical efficacy in a total of 12 cases, namely 3 cases of endometritis, 3 cases of intrapelvic infections, 4 cases of adnexitis and 2 cases of external genital infections. In all the cases, CAZ was administered by intravenous drip infusion, and the duration of the treatment ranged from 3 to 22 days. Daily dose was 2 g in 10 cases, and in the remaining 2 cases, daily doses were changed during the course of treatment in the range from 2 to 4 g. The clinical results of CAZ by disease were as follows; excellent in 1 case and good in 2 cases of endometritis, good in all the 3 cases of intrapelvic infections and the 4 cases of adnexitis, and excellent in 1 case and good in 1 case of external genital infections. The overall efficacy rate was 100%, namely, excellent in 2 cases and good in 10 cases of the total of 12 cases. Neither side effects nor abnormal laboratory findings attributable to CAZ were observed in any of the case. From these results, we may conclude that CAZ is a safe antibiotic with satisfactory clinical effects on gynecological infections.
    [Abstract] [Full Text] [Related] [New Search]